Hematologic profile and complications in patients with ET according to JAK2 genotype
. | JAK2 genotype . | . | . | P . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | Tnull; wild type . | Tminor; T allele up to 50% . | Tmajor; T allele more than 50% . | Global . | Tnull vs Tminor . | Tminor vs Tmajor . | ||||
| No. of patients | 30 | 26 | 5 | — | — | — | ||||
| Age at diagnosis, y (range) | 42 (16-77) | 61 (20-86) | 61 (31-71) | .18 | .11 | .71 | ||||
| Age at inclusion, y (range) | 47 (16-81) | 64 (20-89) | 75 (44-78) | .05 | .07 | .26 | ||||
| Duration of the disease, mo (range) | 43 (0-287) | 54 (0-187) | 156 (79-243) | .03 | .49 | .02 | ||||
| Hematologic profile | ||||||||||
| White blood cell count, × 109/L (range) | 8 (5-16) | 9 (6-21) | 11 (7-16) | .12 | .06 | .78 | ||||
| Platelet count, × 109/L (range) | 875 (510-2000) | 818 (500-1100) | 878 (700-1144) | .52 | .37 | .29 | ||||
| Hemoglobin level, g/L (range) | 141 (113-180) | 145 (129-172) | 134 (123-140) | .03 | .06 | .012 | ||||
| Hematocrit, % (range) | 43 (34-52) | 45 (39-51) | 40 (38-43) | .05 | .05 | .06 | ||||
| Splenomegaly, yes/no | 3/25 | 1/25 | 2/3 | .05 | .61 | .06 | ||||
| EEC, yes/no | 16/14 | 22/4 | 2/3 | .02 | .02 | .06 | ||||
| Complications | ||||||||||
| Follow-up, y (range) | 6 (0.2-24) | 5 (0.6-15) | 17 (9-23) | .06 | .58 | .02 | ||||
| Treatment, yes/no | 19/10 | 21/5 | 4/0 | .21 | .24 | .99 | ||||
| Thrombotic events, yes/no | 7/23 | 8/18 | 0/5 | .33 | .53 | .29 | ||||
| Probabilities of hematologic complications, % | ||||||||||
| 5 y after diagnosis | 0 | 0 | 0 | — | — | — | ||||
| 10 y after diagnosis | 0 | 0 | 20 ± 10 | .01 | NE | .03 | ||||
| Survival rates, % | ||||||||||
| 10 y after diagnosis | 100 | 87 ± 12 | 80 ± 18 | — | — | — | ||||
| 15 y after diagnosis | 100 | 87 ± 12 | 53 ± 25 | .18 | — | — | ||||
. | JAK2 genotype . | . | . | P . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
. | Tnull; wild type . | Tminor; T allele up to 50% . | Tmajor; T allele more than 50% . | Global . | Tnull vs Tminor . | Tminor vs Tmajor . | ||||
| No. of patients | 30 | 26 | 5 | — | — | — | ||||
| Age at diagnosis, y (range) | 42 (16-77) | 61 (20-86) | 61 (31-71) | .18 | .11 | .71 | ||||
| Age at inclusion, y (range) | 47 (16-81) | 64 (20-89) | 75 (44-78) | .05 | .07 | .26 | ||||
| Duration of the disease, mo (range) | 43 (0-287) | 54 (0-187) | 156 (79-243) | .03 | .49 | .02 | ||||
| Hematologic profile | ||||||||||
| White blood cell count, × 109/L (range) | 8 (5-16) | 9 (6-21) | 11 (7-16) | .12 | .06 | .78 | ||||
| Platelet count, × 109/L (range) | 875 (510-2000) | 818 (500-1100) | 878 (700-1144) | .52 | .37 | .29 | ||||
| Hemoglobin level, g/L (range) | 141 (113-180) | 145 (129-172) | 134 (123-140) | .03 | .06 | .012 | ||||
| Hematocrit, % (range) | 43 (34-52) | 45 (39-51) | 40 (38-43) | .05 | .05 | .06 | ||||
| Splenomegaly, yes/no | 3/25 | 1/25 | 2/3 | .05 | .61 | .06 | ||||
| EEC, yes/no | 16/14 | 22/4 | 2/3 | .02 | .02 | .06 | ||||
| Complications | ||||||||||
| Follow-up, y (range) | 6 (0.2-24) | 5 (0.6-15) | 17 (9-23) | .06 | .58 | .02 | ||||
| Treatment, yes/no | 19/10 | 21/5 | 4/0 | .21 | .24 | .99 | ||||
| Thrombotic events, yes/no | 7/23 | 8/18 | 0/5 | .33 | .53 | .29 | ||||
| Probabilities of hematologic complications, % | ||||||||||
| 5 y after diagnosis | 0 | 0 | 0 | — | — | — | ||||
| 10 y after diagnosis | 0 | 0 | 20 ± 10 | .01 | NE | .03 | ||||
| Survival rates, % | ||||||||||
| 10 y after diagnosis | 100 | 87 ± 12 | 80 ± 18 | — | — | — | ||||
| 15 y after diagnosis | 100 | 87 ± 12 | 53 ± 25 | .18 | — | — | ||||
NE indicates not evaluable; —, not calculated.